Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology ...

Panasonic has rung the changes on this second edition of its full-frame flagship. The Lumix S1R II improves upon the original S1R in every key area, battery life excepted. For me, the most ...

Biogen Inc. has a 1-year low of $128.51 and a 1-year high of $238.00. The company has a 50 day moving average price of $144.43 and a 200 day moving average price of $168.73.

Highlights,Truist Financial Corp adjusted its holdings in Biogen Inc., reducing its stake during the fourth quarter.,Multiple institutional investors modified their positions, contributing to overall ...

Biogen Idec, Inc., and Biocon Limited. In any market research analysis, the main field is competition. This segment of the report provides a competitive scenario and portfolio of the Oncology ...

On Wednesday, Goldman Sachs (NYSE:GS) reiterated its Buy rating on Biogen (NASDAQ:BIIB) with a maintained price target of $290.00. The firm's analysis acknowledged Biogen's ...

The tomb of Pharaoh Thutmose II is the first royal crypt discovered in recent years, and scientists have new powerful tools to analyze it. Egypt's Valley of the Kings is part of a massive ...

Biogen Inc. (BIIB), based in Cambridge, Massachusetts, is a leading biotechnology company focused on developing and delivering innovative therapies for neurological and neurodegenerative diseases ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...

Baseball is officially back and the journey to the big show continues for a pair of West Virginia products who are in the St. Louis Cardinals's system - JJ Wetherholt and Victor Scott II.